Alan Pollack

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02
    Alan Pollack
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin Cancer Res 15:5478-84. 2009
  2. ncbi MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
    Li Yan Khor
    Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
    J Clin Oncol 27:3177-84. 2009
  3. ncbi Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
  4. ncbi The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
  5. ncbi The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
    Cancer 100:538-43. 2004
  6. ncbi Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
  7. ncbi Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer
    Niraj Pahlajani
    Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
    Int J Radiat Oncol Biol Phys 82:1949-56. 2012
  8. ncbi Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
  9. ncbi Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
  10. ncbi Hazards of dose escalation in prostate cancer radiotherapy
    Deborah Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:1260-8. 2003

Research Grants

Detail Information

Publications80

  1. ncbi The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02
    Alan Pollack
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Clin Cancer Res 15:5478-84. 2009
    ..Here, we attempt to verify our prior findings and test the hypothesis that the relationship of the length of AD to patient outcome is affected by PKA(RIalpha) overexpression...
  2. ncbi MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02
    Li Yan Khor
    Department of Radiation Oncology, University of Miami, Sylvester Comprehensive Cancer Center, 1475 NW 12th Ave, Suite 1501, Miami, FL 33130, USA
    J Clin Oncol 27:3177-84. 2009
    ..CONCLUSION Combined MDM2 and Ki-67 expression levels were independently related to distant metastasis and mortality and, if validated, could be considered for risk stratification of patients with prostate cancer in clinical trials...
  3. ncbi Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202
    Arnab Chakravarti
    Massachusetts General Hospital Harvard Medical School, Department of Radiation Oncology, Boston, MA 02114, USA
    J Clin Oncol 25:3082-9. 2007
    ..In the present study, we examined the prognostic value of p16 expression in men with locally advanced prostate cancer who were enrolled on Radiation Therapy Oncology Group protocol 9202...
  4. ncbi The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ..Intensity-modulated radiation therapy may offer further reductions in the doses received by the PB and CB; however, at what cost to prostate coverage and normal tissue sparing will be the subject of a follow-up study...
  5. ncbi The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111-2497, USA
    Cancer 100:538-43. 2004
    ..CONCLUSIONS: Escalation of RT dose reduced the rates of BF, DM, and OM significantly in patients with prostate cancer. The inclusion of YOT had a pronounced effect on these correlations that may confound interpretation...
  6. ncbi Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo
    Radka Stoyanova
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:1151-60. 2007
    ..To test the effects of antisense (AS)-MDM2 alone and with androgen deprivation (AD), radiotherapy (RT), and AD + RT on wild-type LNCaP cells in an orthotopic in vivo model...
  7. ncbi Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer
    Niraj Pahlajani
    Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
    Int J Radiat Oncol Biol Phys 82:1949-56. 2012
    ..However, local failure is also a major problem. We sought to establish the importance of more aggressive local radiotherapy (RT) to ≥80 Gy...
  8. ncbi Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Stephen F Andrews
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:299-304. 2005
    ..There are limited data on the consequences of radiation treatment delay. The purpose of the current study was to evaluate the effect of time to treatment (TTT) on outcomes...
  9. ncbi Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  10. ncbi Hazards of dose escalation in prostate cancer radiotherapy
    Deborah Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 57:1260-8. 2003
    ..To assess the benefit of escalating the dose in definitive prostate cancer radiotherapy vs. the associated risk of complications...
  11. ncbi Comparing computed tomography localization with daily ultrasound during image-guided radiation therapy for the treatment of prostate cancer: a prospective evaluation
    Steven J Feigenberg
    Fox Chase Cancer Center, Department of Radiation Oncology, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 8:2268. 2007
    ..The isocenter shifts generated by using a CT unit in the treatment room correlate highly with shifts produced by the BAT Ultrasound system...
  12. ncbi What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  13. ncbi Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 70:67-74. 2008
    ..To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer...
  14. ncbi The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  15. ncbi Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement
    Rojymon Jacob
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:695-701. 2005
    ..These data suggest that the primary tumor takes precedence over lymph node coverage or the use of STAD. Doses >70 Gy are of paramount importance in such intermediate- and high-risk patients...
  16. ncbi Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 68:599-609. 2008
    ..In this study, we investigated the effects of AS-MDM2 combined with AD on androgen resistant LNCaP (LNCaP-Res) and moderately androgen resistant bcl-2 overexpressing LNCaP (LNCaP-BST) cells...
  17. ncbi What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 61:1003-10. 2005
    ..The purpose of this study was to determine what pretreatment (initial) PSA (iPSA) level, if any, warrants the addition of long-term androgen deprivation in the PSA era...
  18. ncbi A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
    ..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
  19. ncbi Long-term androgen deprivation increases Grade 2 and higher late morbidity in prostate cancer patients treated with three-dimensional conformal radiation therapy
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 62:397-405. 2005
    ..To determine whether the use of androgen deprivation (AD) increases late morbidity when combined with high-dose three-dimensional conformal radiation therapy (3D-CRT)...
  20. ncbi Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial
    Mack Roach
    Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA
    Int J Radiat Oncol Biol Phys 69:79-87. 2007
    ..To understand how variation in CYP3A4 correlated with outcomes, a retrospective examination of the CYP3A4 *1B genotype was performed on men treated with Radiation Therapy Oncology Group (RTOG) 92-02...
  21. ncbi Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  22. ncbi Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Clin Cancer Res 13:3585-90. 2007
    ..A follow-up investigation was carried out here in more contemporary high-risk men treated on Radiation Therapy Oncology Group 92-02 with STAD+RT or long-term AD+RT (LTAD+RT)...
  23. ncbi Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer
    Navesh K Sharma
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 80:437-44. 2011
    ..The present study compared the genitourinary and gastrointestinal (GI) toxicity in men treated with 3D-CRT+AD vs. IMRT+AD...
  24. ncbi Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10
    Li Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 71:1309-15. 2008
    ....
  25. ncbi Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  26. ncbi How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  27. ncbi Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  28. ncbi Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:19-23. 2003
    ..However, little evidence is available to show that BF is associated with death for patents with prostate cancer treated with radiotherapy. We examined the relationship between BF and death from prostate cancer...
  29. ncbi Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer
    Alexandra L Hanlon
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:43-52. 2004
    ....
  30. ncbi Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The American Society of Therapeutic Radiation Oncology definition for biochemical failure overestimates BF in 20-30% after RT+AD compared to 5% after RT alone...
  31. ncbi Magnetic resonance-based treatment planning for prostate intensity-modulated radiotherapy: creation of digitally reconstructed radiographs
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:903-11. 2007
    ....
  32. ncbi A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111-2497, USA
    Int J Radiat Oncol Biol Phys 59:380-5. 2004
    ..CONCLUSIONS: The SF model created prognostic groups with a greater internal consistency than the DF model. The SF was also better at identifying patients with high-risk prostate cancer who may benefit from a more aggressive approach...
  33. ncbi Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy
    Mary Feng
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109 0010, USA
    Int J Radiat Oncol Biol Phys 68:1417-23. 2007
    ..To determine the rate and magnitude of late genitourinary (GU) and gastrointestinal (GI) toxicities after salvage or adjuvant radiotherapy (RT) for prostate cancer, and to determine predictive factors for these toxicities...
  34. ncbi A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer
    Steven J Feigenberg
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Am J Clin Oncol 29:458-62. 2006
    ..The purpose of this report is to determine whether any specific magnitude in the prostate specific antigen (PSA) bounce predicted for a clinically poorer outcome...
  35. ncbi Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 60:187-96. 2004
    ..Antisense MDM2 has broad potential as a therapeutic agent to sensitize prostate cancer cells to AD therapy by enhancing apoptotic cell death...
  36. ncbi Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
    Jeff M Michalski
    Department of Radiation Oncology, Washington University, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 56:192-8. 2003
    ..To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406...
  37. ncbi Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA, USA
    J Clin Oncol 25:3603-8. 2007
    ..The specific aim of this study was to examine the cost effectiveness of proton beam radiation compared with current state-of-the art therapy in the treatment of patients with prostate cancer. Materials and..
  38. ncbi Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?
    Deborah A Kuban
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 79:1310-7. 2011
    ..To report long-term failure patterns and survival in a randomized radiotherapy dose escalation trial for prostate cancer...
  39. ncbi Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?
    Khanh H Nguyen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:377-83. 2003
    ....
  40. ncbi Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone
    Eric M Horwitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Urol 169:2153-7; discussion 2157-9. 2003
    ..Additional analysis with large numbers of patients from multiple institutions is necessary to determine the point...
  41. ncbi Gains from real-time tracking of prostate motion during external beam radiation therapy
    Jin sheng Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 75:1613-20. 2009
    ..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
  42. ncbi Does age matter in the selection of treatment for men with early-stage prostate cancer?
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 106:2598-602. 2006
    ....
  43. ncbi The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms
    Radka Stoyanova
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Cancer 119:1080-8. 2013
    ..The authors designed a model to estimate the results of various doses of radiotherapy (RT) combined with various durations of ADT...
  44. ncbi MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Phys Med Biol 57:535-45. 2012
    ....
  45. ncbi Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10
    Li-Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:25-30. 2006
    ..The cohort examined was comprised of patients with locally advanced disease and it is possible that these markers may be of greater value in men with earlier-stage prostate cancer...
  46. ncbi Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
    ..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
  47. ncbi Does treatment duration affect outcome after radiotherapy for prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 72:1402-7. 2008
    ..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
  48. ncbi Experience of ultrasound-based daily prostate localization
    Anurag Chandra
    Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 56:436-47. 2003
    ..Although the accuracy of the BAT was not addressed in this investigation, we found a significant percentage of large shifts being made from the initial alignment position...
  49. ncbi Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 71:938-41. 2008
    ..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
  50. ncbi Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 109:2011-5. 2007
    ..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
  51. ncbi Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 54:677-85. 2002
    ..These issues were investigated in a cohort of men with Stage T1-T3 prostate cancer who were randomized to receive between 70 Gy and 78 Gy and were prospectively biopsied at about 2 years after the completion of radiotherapy (RT)...
  52. ncbi MRI-based treatment planning for radiotherapy: dosimetric verification for prostate IMRT
    Lili Chen
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 60:636-47. 2004
    ....
  53. ncbi Target localization for post-prostatectomy patients using CT and ultrasound image guidance
    Kamen Paskalev
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Appl Clin Med Phys 6:40-9. 2005
    ..However, ultrasound alignments performed without the use of a template deteriorated patient positioning for two out of three patients, demonstrating that the use of a CT template was beneficial even at small initial displacements...
  54. ncbi MDM2 as a predictor of prostate carcinoma outcome: an analysis of Radiation Therapy Oncology Group Protocol 8610
    Li-Yan Khor
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 104:962-7. 2005
    ..CONCLUSIONS: MDM2 expression quantified by image analysis was weakly associated with DM. The cohort examined was relatively small and with larger patient numbers, MDM2 overexpression may emerge as a more significant covariate...
  55. ncbi Adenovirus E2F1 overexpression sensitizes LNCaP and PC3 prostate tumor cells to radiation in vivo
    Thirupandiyur S Udayakumar
    Department of Radiation Oncology, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, Florida, USA
    Int J Radiat Oncol Biol Phys 79:549-58. 2011
    ..Here, we demonstrate the radiosensitization efficacy of adenovirus (Ad)-E2F1 infection in growing (orthotopic) LNCaP and (subcutaneous) PC3 nude mice xenograft tumors...
  56. ncbi Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
    Pino Alcantara
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 109:41-7. 2007
    ..0001).CONCLUSIONS.nPSA12 is a strong independent predictor of outcome after RT alone for prostate cancer and should be useful in identifying patients at high risk for progression to metastasis and death...
  57. ncbi Mindless or mindful? Radiation oncologists' perspectives on the evolution of prostate cancer treatment
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Urol Clin North Am 30:337-49, x. 2003
    ..In summary, advances in radiation oncology have led to significant gains in prostate cancer control. Clinical prognostic factor-based patient selection is central to the optimization of outcome...
  58. ncbi The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  59. ncbi Is 6 months of androgen suppression therapy plus radiotherapy of benefit in patients with localized prostate cancer?
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Nat Clin Pract Oncol 2:12-3. 2005
  60. ncbi The Gleason score shift: score four and seven years ago
    Derek B Chism
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 56:1241-7. 2003
    ..The GS shift confounds retrospective series spanning the 1990s...
  61. ncbi Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..04). CONCLUSIONS: Inclusion of positive biopsy laterality status into clinical staging causes stage migration without reflecting a change in outcome and should not be used...
  62. ncbi Influence of number of CAG repeats on local control in the RTOG 86-10 protocol
    May Abdel-Wahab
    Department of Radiation Oncology, University of Miami School of Medicine, Miami, FL 33136, USA
    Am J Clin Oncol 29:14-20. 2006
    ..The purpose of this study was to determine if short-term androgen deprivation therapy (RT + HT) can improve outcome in patients with tumors with short CAG repeats (<19)...
  63. ncbi Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:743-9. 2004
    ..A Phase III randomized trial has been designed to test the clinical significance of the erectile tissue-sparing technique described here...
  64. ncbi Quality-of-life questionnaire results 2 and 3 years after radiotherapy for prostate cancer in a randomized dose-escalation study
    Darren J Little
    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    Urology 62:707-13. 2003
    ..Comparing the results 2 and 3 years after radiotherapy, the symptoms of rectal bleeding had improved, erectile function had decreased, and urinary urge incontinence had increased...
  65. ncbi Prostate cancer radiotherapy dose response: an update of the fox chase experience
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    J Urol 171:1132-6. 2004
    ....
  66. ncbi Parameters for treatment decisions for salvage radiation therapy
    Shelly Bowers Hayes
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    J Clin Oncol 23:8204-11. 2005
    ..These factors should be used as a guide to the options of local therapy alone (RT), local therapy plus systemic therapy (typically androgen deprivation therapy), and systemic therapy alone...
  67. ncbi Antisense Bcl-2 sensitizes prostate cancer cells to radiation
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Prostate 65:331-40. 2005
    ..CONCLUSIONS: To our knowledge, these data demonstrate for the first time that a Bcl-2 specific AS oligonucleotide sensitizes prostate cancer cells to RT. p53 is not required for this effect...
  68. ncbi Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:22-30; discussion 30-1. 2002
    ..The results with long-term ADT are much more convincing than short-term ADT, and, as a consequence, 2 to 3 years are recommended...
  69. ncbi Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings
    Benjamin Movsas
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 60:634-9. 2002
    ..The P/M PO2 ratio was the strongest predictor for biochemical control on stepwise multivariate analysis. Longer follow up with more patients is planned to confirm this result...
  70. ncbi Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 97:1630-8. 2003
    ..The current study examined the association between expression levels of Ki-67, bcl-2, bax, and bcl-x in pretreatment biopsy specimens and patient outcome after definitive radiotherapy alone...
  71. ncbi Treatment of prostate cancer with regional lymph node (N1) metastasis
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 13:121-9. 2003
    ..Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP...
  72. ncbi Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination
    Zhaomei Mu
    Department of Radiation Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 58:336-43. 2004
    ..CONCLUSION: AS sensitizes cells to AD, RT, and AD+RT and shows promise in the treatment of the full range of patients with prostate cancer. AS has the potential to sensitize the primary tumor to AD+RT and metastasis to AD...
  73. ncbi Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial
    Alan Pollack
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Radiat Oncol Biol Phys 53:1097-105. 2002
    ..A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer...
  74. ncbi Radiation therapy dose escalation for prostate cancer: a rationale for IMRT
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    World J Urol 21:200-8. 2003
    ..The results of dose escalation, the ability of IMRT to reduce rectal and bladder exposure to high radiation doses and the use of new imaging methods to more accurately target the prostate are described...
  75. ncbi Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer
    Eugene H Huang
    Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 54:1314-21. 2002
    ..Therefore, dose escalation may be safely achieved by adherence to dose-volume histogram constraints during treatment planning and organ localization at the time of treatment to ensure consistent patient setup...
  76. ncbi A method for increased dose conformity and segment reduction for SMLC delivered IMRT treatment of the prostate
    Robert A Price
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 57:843-52. 2003
    ..The focus of this work is to develop a practical planning method that results in increased dose conformity and reduced treatment time for segmental multileaf collimation (sMLC) based intensity-modulated radiation therapy (IMRT) delivery...
  77. ncbi Postprostatectomy radiation therapy for prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Semin Radiat Oncol 18:15-22. 2008
    ..Because the morbidity of postoperative radiotherapy is relatively low, when pathologic high risk factors are present adjuvant radiotherapy should be considered. The role of androgen deprivation postprostatectomy is less well defined...
  78. ncbi Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer
    Andre Konski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 66:408-15. 2006
    ....
  79. ncbi Assessment of external beam radiation technology for dose escalation and normal tissue protection in the treatment of prostate cancer
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:671-7. 2008
  80. ncbi Predictive models in external beam radiotherapy for clinically localized prostate cancer
    Mack Roach
    Department of Radiation Oncology, University of California at San Francisco, San Francisco, California, USA
    Cancer 115:3112-20. 2009
    ..Cancer 2009;115(13 suppl):3112-20. (c) 2009 American Cancer Society...

Research Grants5

  1. Radiation, Hormones & Antisense Prostate Cancer Therapy
    Alan Pollack; Fiscal Year: 2007
    ..abstract_text> ..